KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)

Historical Holders from Q4 2016 to Q4 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Symbol: KALV on Nasdaq
Shares outstanding: 50,232,186
Price per share: $16.15
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares: 58,631,944
Total reported value: $714,167,714
% of total 13F portfolios: 0%
Share change: +4,161,279
Value change: +$51,926,504
Number of holders: 143
Price from insider filings: $16.15

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
TANG CAPITAL MANAGEMENT LLC	9.9%		$52,086,551		4,941,798		TANG CAPITAL MANAGEMENT, LLC	31 Mar 2025
Frazier Life Sciences Public Fund, L.P.	6.9%	+42%	$42,222,226	+$12,986,864	3,466,521	+44%	Frazier Life Sciences Public Fund, L.P.	01 Nov 2025
Capital World Investors	6.4%		$33,491,767		3,177,587		Capital World Investors	31 Mar 2025
MILLENNIUM MANAGEMENT LLC	5.9%	+18%	$39,595,019	+$5,780,725	2,963,699	+17%	Millennium Management LLC	23 Dec 2025
Vestal Point Capital, LP	1.5%		$9,135,000		750,000		Vestal Point Capital, LP	30 Sep 2025

As of 30 Sep 2025, KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) has 143 institutional shareholders filing 13F forms. They hold 58,631,944 shares. .

Top 25 institutional shareholders own 102% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
VR ADVISER, LLC	13%	6,728,985	0%	4.6%	$81,959,037
TANG CAPITAL MANAGEMENT LLC	10%	5,041,798	+2%	2.4%	$61,409,100
Frazier Life Sciences Management, L.P.	10%	5,039,867	+3.1%	1.8%	$61,385,580
SUVRETTA CAPITAL MANAGEMENT, LLC	9.5%	4,768,712	-3.8%	1.8%	$58,082,912
Capital World Investors	6.3%	3,177,587	0%	0.01%	$38,703,010
BlackRock, Inc.	6.2%	3,126,117	-0.11%	0%	$38,076,105
VANGUARD GROUP INC	5%	2,501,119	+3.7%	0%	$30,463,629
MILLENNIUM MANAGEMENT LLC	4.2%	2,096,223	+515%	0.02%	$25,531,996
Woodline Partners LP	3.8%	1,920,664	0%	0.11%	$23,393,688
GOLDMAN SACHS GROUP INC	3.6%	1,800,181	+1239%	0%	$21,926,205
Parkman Healthcare Partners LLC	3.5%	1,735,003	+155%	2.3%	$21,132,337
STATE STREET CORP	3.1%	1,575,496	+17%	0%	$19,189,541
SILVERARC CAPITAL MANAGEMENT, LLC	2.7%	1,363,378	-26%	2.4%	$16,605,944
EMERALD ADVISERS, LLC	2.7%	1,351,254	+30%	0.53%	$16,458,274
Octagon Capital Advisors LP	2.5%	1,273,333	0%	2.4%	$15,509,196
SCHRODER INVESTMENT MANAGEMENT GROUP	2.3%	1,158,457	+109%	0.01%	$14,144,760
GEODE CAPITAL MANAGEMENT, LLC	1.8%	928,671	-1.3%	0%	$11,313,517
EMERALD MUTUAL FUND ADVISERS TRUST	1.8%	917,975	+19%	0.58%	$11,180,936
Vestal Point Capital, LP	1.5%	750,000	-84%	0.41%	$9,135,000
Freestone Grove Partners LP	1.4%	704,448		0.06%	$8,580,177
Sio Capital Management, LLC	1.4%	683,819		2.1%	$8,328,915
Kynam Capital Management, LP	1.2%	606,171		0.55%	$7,383,163
Bank of New York Mellon Corp	1.2%	596,474	+454%	0%	$7,265,054
BARCLAYS PLC	1.2%	577,904	+242%	0%	$7,038,871
MORGAN STANLEY	1.1%	564,855	+136%	0%	$6,879,937

Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	60,203	$972,595	+$275,917			$16.15	5
2025 Q3	58,631,944	$714,167,714	+$51,926,504	$10,530,828	$14,084,952	$12.18	143
2025 Q2	54,445,883	$615,513,091	-$5,352,598	$1,018,581	$11,482,419	$11.30	138
2025 Q1	54,890,685	$633,782,168	+$5,364,855	$69,240	$13,633,356	$11.54	127
2024 Q4	55,190,249	$467,414,125	+$30,397,004	$310,002	$114,345	$8.47	129
2024 Q3	48,412,221	$560,958,386	+$550,126	$1,277,274	$5,802,738	$11.58	120
2024 Q2	48,235,227	$568,211,500	+$14,329,311	$309,814	$256,804	$11.78	118
2024 Q1	46,977,159	$557,147,902	+$118,361,057	$853,920	$748,366	$11.86	127
2023 Q4	12,539	$153,603	-$71,643			$12.25	1
2023 Q3	36,263,336	$349,220,972	+$17,907,372	$4,022,451	$10,553,517	$9.63	101
2023 Q2	34,451,516	$310,062,975	+$8,856,436	$958,500	$739,800	$9.00	93
2023 Q1	33,720,468	$265,038,656	-$7,296,084	$0	$5,502	$7.86	87
2022 Q4	33,810,837	$228,557,377	+$23,549,943	$89,908	$1,026,844	$6.76	88
2022 Q3	25,554,803	$370,795,783	+$16,611,402		$8,075,500	$14.51	85
2022 Q2	24,193,911	$238,066,172	-$18,124,235		$4,933,000	$9.84	83
2022 Q1	23,880,152	$352,009,504	+$6,707,292	$0	$1,634,000	$14.74	79
2021 Q4	23,784,064	$314,614,009	-$24,155,323	$138,000	$164,000	$13.23	93
2021 Q3	23,367,778	$408,011,803	-$21,469,346	$2,532,000	$514,000	$17.45	101
2021 Q2	24,234,176	$580,656,986	+$10,755,666	$3,702,000	$2,405,000	$23.96	108
2021 Q1	23,504,825	$603,806,034	+$241,535,569	$7,622,000	$3,486,000	$25.69	114
2020 Q4	14,627,574	$277,764,932	+$4,583,782	$6,364,000	$5,070,000	$18.99	78
2020 Q3	15,642,000	$196,878,450	+$2,825,299			$12.59	60
2020 Q2	15,986,858	$193,667,544	+$9,418,795			$12.10	72
2020 Q1	15,622,520	$119,504,221	+$17,285,176			$7.65	67
2019 Q4	13,678,308	$243,587,076	+$13,387,676			$17.81	71
2019 Q3	13,183,427	$152,925,098	-$33,967,366			$11.60	74
2019 Q2	14,785,410	$327,483,694	+$6,255,781			$22.15	73
2019 Q1	13,905,857	$397,892,000	+$23,848,401			$28.62	67
2018 Q4	12,995,704	$256,397,000	+$10,739,559			$19.75	55
2018 Q3	12,319,459	$270,617,769	+$110,908,440			$22.11	46
2018 Q2	6,316,266	$51,280,000	-$1,576,548			$8.12	24
2018 Q1	6,502,090	$61,589,000	+$133,888			$9.48	22
2017 Q4	6,483,901	$63,212,000	-$2,998,186			$9.75	22
2017 Q3	7,715,060	$52,230,000	+$2,314,856			$6.73	15
2017 Q2	7,368,296	$54,073,000	-$1,766,452			$7.36	16
2017 Q1	7,587,249	$59,160,000	+$2,023,036			$7.81	17
2016 Q4	7,331,083	$51,493,000	+$46,973,881			$7.07	18